Zepbound vs Mounjaro: Cost and Access Head-to-Head

Same Molecule, Different Label

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It is identical in both products. The peptide sequence, the manufacturing process, and the subcutaneous injection delivery are the same whether the pharmacy dispenses a Zepbound pen or a Mounjaro pen [1]. What differs is the regulatory approval pathway Eli Lilly pursued for each brand name.

Mounjaro received FDA approval in May 2022 as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes [2]. Zepbound followed in November 2023 for chronic weight management in adults meeting BMI criteria [3]. This split-label strategy means the same 15 mg tirzepatide injection can carry two different NDC codes, two different formulary positions, and two very different insurance outcomes. The clinical pharmacology does not change. The billing does.

Lilly prices both products within roughly $40 of each other at wholesale acquisition cost. But retail price is almost irrelevant for most patients. What matters is whether the insurer classifies the prescription as a covered diabetes drug or a non-covered obesity drug, and that distinction drives a cost gap that can exceed $1,000 per month out of pocket.

Clinical Efficacy: What the Trials Showed

Because Zepbound and Mounjaro deliver the same active compound, their efficacy profiles are complementary rather than competitive. No head-to-head trial of Zepbound versus Mounjaro exists (and designing one would be unusual, given molecular identity). The relevant evidence base spans the SURMOUNT program (obesity) and the SURPASS program (type 2 diabetes).

In SURMOUNT-1 (N=2,539), participants without diabetes receiving tirzepatide 15 mg achieved 20.9% mean body-weight loss at 72 weeks compared with 3.1% in the placebo group [4]. The 10 mg dose produced 19.5% loss, and the 5 mg dose produced 15.0% loss. These results established tirzepatide as the most effective anti-obesity medication studied in a phase 3 program at the time of publication.

In SURPASS-2 (N=1,879), adults with type 2 diabetes on metformin were randomized to tirzepatide 5 mg, 10 mg, or 15 mg versus semaglutide 1 mg [5]. Tirzepatide 15 mg reduced HbA1c by 2.46 percentage points versus 1.86 points with semaglutide. Weight loss was also greater: 12.4 kg with tirzepatide 15 mg versus 6.2 kg with semaglutide 1 mg at 40 weeks. The trial demonstrated that tirzepatide outperformed semaglutide on both glycemic and weight endpoints in a T2D population.

These two programs share the same molecule at the same doses. A patient prescribed Mounjaro 10 mg for diabetes will experience the same pharmacologic effect as a patient prescribed Zepbound 10 mg for obesity. The FDA indication does not alter the drug's mechanism of action. It alters the reimbursement pathway.

Insurance Coverage and Formulary Differences

This is where the practical gap between Zepbound and Mounjaro becomes wide. Commercial health plans in the United States are far more likely to cover Mounjaro for a type 2 diabetes diagnosis than Zepbound for an obesity diagnosis.

The reason is structural. Employer-sponsored plans have covered diabetes medications for decades. Anti-obesity medications (AOMs) are a newer formulary category, and many plan sponsors still exclude them or restrict them behind step therapy, prior authorization, and quantity limits. A 2024 analysis by the Obesity Action Coalition found that fewer than 40% of large employer plans covered any GLP-1 receptor agonist for weight management, while coverage for the same drugs under a diabetes indication exceeded 80% [6].

Mounjaro typically sits on Tier 3 or Tier 4 of commercial formularies when prescribed for T2D. With the Lilly Mounjaro Savings Card, commercially insured patients with coverage may pay as little as $25 per 1-month or 3-month prescription. Without a savings card, the Tier 3 copay commonly ranges from $75 to $150 per fill.

Zepbound's formulary position is less predictable. Some insurers (Aetna, select Blue Cross Blue Shield plans, and certain UnitedHealthcare policies) began adding Zepbound to formularies in 2024. Others explicitly exclude it. When Zepbound is excluded, patients face the full list price of roughly $1,060 per month. The Zepbound Savings Card can reduce commercial copays to $25 for eligible patients, but eligibility requires that the patient's plan covers the drug in the first place or that the patient meets specific uninsured criteria.

Medicare and Medicaid: The Federal Coverage Gap

Medicare Part D does not cover drugs prescribed for weight loss. This exclusion traces back to the Medicare Modernization Act of 2003, which categorized AOMs alongside cosmetic drugs and fertility agents as statutorily excluded [7]. Zepbound, when prescribed solely for obesity, falls under this exclusion. Patients on Medicare who need tirzepatide for weight management face an annual out-of-pocket cost exceeding $12,000 at current list prices.

Mounjaro can be covered under Medicare Part D when prescribed for type 2 diabetes. This creates a gray zone for patients who have both T2D and obesity. A prescriber documenting T2D as the primary indication may obtain Part D coverage for Mounjaro, and the patient will experience weight loss as a secondary benefit. The prescribing indication, not the patient's full problem list, determines coverage.

Legislative proposals like the Treat and Reduce Obesity Act have attempted to remove the Part D AOM exclusion. As of early 2026, these proposals have not become law. Some Medicare Advantage plans have begun offering supplemental AOM benefits, but this coverage is plan-specific and often limited to a 6- or 12-month course.

Medicaid coverage varies by state. As of 2025, at least 14 state Medicaid programs covered some form of GLP-1 agonist for obesity, but formulary restrictions, preferred drug lists, and prior authorization requirements differ dramatically. A patient in New York may have Zepbound access through Medicaid managed care, while a patient in Texas may face complete exclusion [8].

Out-of-Pocket Cost Comparison

The real-world cost a patient pays depends on four variables: insurance status, formulary tier, manufacturer savings program eligibility, and pharmacy selection. A side-by-side breakdown:

Commercially insured, drug is covered, with savings card: Both Zepbound and Mounjaro can cost as little as $25 per fill. The savings cards cap annual benefits (typically around $150 per fill or a cumulative annual maximum), so patients should verify renewal terms at each calendar year.

Commercially insured, drug is NOT covered: The patient pays list price. For Mounjaro, this is approximately $1,023/month. For Zepbound, approximately $1,060/month. Some patients in this situation use manufacturer programs for the uninsured, which Lilly has priced at $399 to $549 per month for Zepbound (the "Zepbound Direct" vial program launched in late 2024 at lower price points for 2.5 mg and 5 mg doses) [9].

Medicare Part D, diabetes indication: Mounjaro may be covered with standard Part D cost-sharing. After the Inflation Reduction Act's $2,000 annual out-of-pocket cap took effect in 2025, a Medicare patient's total annual Mounjaro cost is capped at $2,000 regardless of list price [10].

Medicare Part D, obesity indication: Zepbound is excluded from Part D. Full cash price applies. Annual cost: $12,720+ at list.

Uninsured: Both products list above $1,000/month at retail. The Zepbound vial program (2.5 mg and 5 mg only) offers lower-cost entry at $399/month. Mounjaro does not have an equivalent vial program as of early 2026.

Prior Authorization: What Gets Approved

Prior authorization (PA) requirements differ between the two brands because they target different therapeutic categories. For Mounjaro prescribed for T2D, most commercial plans require documentation of:

• A confirmed T2D diagnosis (ICD-10 E11.x)
• Current or prior metformin use (unless contraindicated)
• A recent HbA1c value (typically ≥7.0%)
• Trial and failure of at least one formulary-preferred agent (step therapy)

PA approval rates for Mounjaro in T2D are relatively high once step therapy is satisfied. The American Diabetes Association's Standards of Care include GLP-1 receptor agonists and dual GIP/GLP-1 agonists as recommended second-line therapies for patients with T2D and overweight or obesity, giving prescribers strong guideline backing for PA appeals [11].

Zepbound PA criteria for obesity are more variable. Common requirements include:

• BMI ≥30 kg/m² or ≥27 kg/m² with a weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea)
• Documentation of a structured lifestyle modification program (diet and exercise) for 3 to 6 months
• Trial and failure of another AOM (e.g., phentermine, orlistat, naltrexone-bupropion)
• Re-authorization every 6 to 12 months with demonstrated weight loss (often ≥5% from baseline)

Denial rates for AOMs remain higher than for diabetes medications. When a PA is denied, patients can appeal, but the process adds weeks to months of delay. Prescribers who document comorbidity reduction (e.g., blood pressure improvement, reduction in sleep apnea severity) alongside weight loss tend to have higher appeal success rates.

Switching Between Zepbound and Mounjaro

Because tirzepatide is the same compound in both products, switching from one brand to the other requires no dose adjustment, washout period, or re-titration (assuming the patient continues the same dose). The pharmacokinetics do not change with the label.

The reasons patients switch are almost always financial or administrative. A patient on Zepbound whose insurer removes obesity drug coverage mid-year may ask their prescriber to switch to Mounjaro if they also carry a T2D diagnosis. Conversely, a patient stable on Mounjaro who loses T2D formulary coverage (due to a plan change or formulary update) may seek Zepbound if their plan covers AOMs.

Prescribers should document the clinical rationale for the chosen indication. An endocrinologist prescribing Mounjaro for a patient with T2D and obesity is on firm ground. A primary care physician switching a patient from Zepbound to Mounjaro must ensure the patient genuinely meets diagnostic criteria for T2D (fasting glucose ≥126 mg/dL, HbA1c ≥6.5%, or 2-hour OGTT ≥200 mg/dL per ADA Standards of Care) [11]. Prescribing Mounjaro for a patient without diabetes to circumvent obesity drug exclusions is off-label and creates documentation risk.

Pharmacy-level considerations also apply. NDC codes differ between Zepbound and Mounjaro. A switch triggers a new PA in most systems. Patients should expect a 1- to 2-week processing gap and plan to have a bridge supply if possible.

Compounded Tirzepatide: The Third Option

The FDA's drug shortage list included tirzepatide through much of 2024 and into early 2025, which allowed 503A and 503B compounding pharmacies to produce tirzepatide copies. Compounded tirzepatide was available at significantly lower prices (often $300 to $500 per month) but lacked the FDA's full manufacturing oversight [12].

Eli Lilly contested compounding eligibility and the FDA announced in late 2024 that the tirzepatide shortage had been resolved, triggering a phase-out of compounded versions. Legal challenges from compounding pharmacies delayed full enforcement. As of early 2026, the regulatory status of compounded tirzepatide remains in flux, with federal court injunctions in some jurisdictions allowing continued dispensing.

Patients considering compounded tirzepatide should understand the key differences: compounded products do not undergo the same stability, sterility, and potency testing as FDA-approved products. The FDA has warned that adverse events linked to compounded semaglutide and tirzepatide have been reported, including dosing errors and contamination [13]. For patients with insurance coverage for either Zepbound or Mounjaro, the brand-name product with manufacturer quality assurance is the preferred option.

How to Maximize Coverage and Minimize Cost

Patients and prescribers can take specific steps to improve access and reduce out-of-pocket expense for tirzepatide, regardless of brand:

Start with the indication your insurance covers best. If a patient has both T2D and obesity, Mounjaro prescribed for T2D will almost always have a smoother coverage pathway than Zepbound for obesity. This is not gaming the system. The ADA recognizes that weight management is a core component of T2D treatment [11].

Use manufacturer savings programs early. Both the Mounjaro Savings Card and the Zepbound Savings Card have annual limits. Enrolling at the start of the benefit year maximizes the savings window. Verify program terms each January, as Lilly has modified copay card structures annually since 2023.

Appeal denials with clinical documentation. A PA denial is not a final answer. Appeals that include baseline and follow-up weight, HbA1c trends, blood pressure records, and a letter citing ADA or Endocrine Society guidelines have measurably higher overturn rates. The Endocrine Society's 2024 clinical practice guideline on obesity pharmacotherapy provides direct language supporting GLP-1 and dual-agonist use that can be cited in appeal letters [14].

Ask about the Zepbound vial program. For patients initiating therapy at 2.5 mg or 5 mg who are uninsured or whose insurance does not cover the drug, Lilly's single-dose vial presentation launched at $399/month represents a lower entry point than the pen injector's list price.

Check state parity laws. Several states (including New York, Connecticut, and Colorado) have enacted or proposed legislation requiring commercial insurers to cover FDA-approved AOMs in the same manner as other chronic disease medications. Coverage mandates are evolving and may change a patient's access profile within a single plan year.

Patients with a current tirzepatide prescription paying above $550 per month out of pocket should have their prescriber's office re-run a benefits investigation, as formulary additions and savings program updates occur quarterly.